The Impact of Inherited Retinal Diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a Cost-of-Illness Perspective
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
To date, there has been a global lack of data regarding the prevalence of conditions falling under the Inherited Retinal Diseases (IRD) classification, the impact on the individuals and families affected, and the cost burden to economies. The absence of an international patient registry, and equitable access to genetic testing, compounds this matter. The resulting incomplete knowledge of the impact of IRDs hinders the development and commissioning of clinical services, provision of treatments, and planning and implementation of clinical trials. Thus, there is a need for stronger evidence to support value for money to regulatory bodies for treatments approved, and progressing through clinical trials. To ensure a strategic approach to future research and service provision, it is necessary to learn more about the IRD landscape. This review highlights two recent cost-of-illness reports on the socio-economic impact of 10 IRDs in the Republic of Ireland (ROI) and the United Kingdom (UK), which demonstrate the comprehensive impact of IRDs on individuals affected, their families, friends and society. Total costs attributable to IRDs in the ROI were estimated to be £42.6 million in 2019, comprising economic (£28.8 million) and wellbeing costs (£13.8 million). Wellbeing costs were estimated using the World Health Organization (WHO) burden of disease methodology, a non-financial approach, where pain, suffering and premature mortality are measured in terms of disability-adjusted-life-years (DALYs). In the UK, wellbeing costs attributable to IRDs were £196.1 million, and economic costs were £327.2 million amounting to £523.3 million total costs in 2019. Accounting for over one-third of total costs, the wellbeing burden of persons affected by IRDs should be emphasized and factored into reimbursement processes for therapies and care pathways. This targeted review presents the most current and relevant data on IRD prevalence in the ROI and the UK, and the impacts (financial and non-financial) of IRDs in terms of diagnosis, wellbeing, employment, formal and informal care, health system costs, deadweight losses and issues surrounding payers and reimbursement. This review demonstrates IRD patients and their families have common issues including, the need for timely equitable access to genetic testing and counselling, equality in accessing employment, and a revision of the assessment process for reimbursement of therapies currently focused on the cost-of-illness to the healthcare system. This review reveals that IRD patients do not frequently engage the healthcare system and as such suggests a cost-of-illness model from a societal perspective may be a better format.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other international studies suggested that 81% to 90% of the costs associated with IRDs are indirect and intangible [80–84].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health at a Glance 2017: OECD Indicators
OECD (2017) · Health at a Glance · doi:10.1787/health_glance-2017-en · Cited by 768
Minimal Clinically Important Difference: Defining What Really Matters to Patients
McGlothlin, A. E., & Lewis, R. J. (2014) · JAMA · doi:10.1001/jama.2014.13128 · Cited by 703
A 2020 vision of patient-centered primary care
Davis, K., Schoenbaum, S. C., & Audet, A.-M. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0178.x · Cited by 683
Richter, T., Nestler-Parr, S., Babela, R., Khan, Z. M., Tesoro, T., Molsen, E., & Hughes, D. A. (2015) · Value in Health · doi:10.1016/j.jval.2015.05.008 · Cited by 590
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409 · cited 1×
“16 Typically, such trials and treatments require that a causative variant has been identi fi ed in order to participate.”
Cost of stroke in the United Kingdom
Saka, O., McGuire, A., & Wolfe, C. (2008) · Age and Ageing · doi:10.1093/ageing/afn281 · Cited by 337
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
Cost of cardiovascular diseases in the United Kingdom
Luengo-Fernández, R., Leal, J., Gray, A., Petersen, S., & Rayner, M. (2006) · Heart · doi:10.1136/hrt.2005.072173 · Cited by 203
A shorter working week for everyone: How much paid work is needed for mental health and well-being?
Kamerāde, D., Wang, S., Burchell, B. J., Balderson, U., & Coutts, A. P. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.06.006 · Cited by 176
Visual Function, Social Position, and Health and Life Chances: The UK Biobank Study
Cumberland, P. M., Rahi, J. S., & for the UK Biobank Eye and Vision Consortium (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.1778 · Cited by 160
Research works printed but not linked: 6
- Sergouniotis, 2019, Ophthalmologica, 5, 1
- Stuart, 2018, Eye Net Mag, 2018, 43
- Zhao, 2019, J Ophthalmol, 21, 8524607
- 2014, Registries for Evaluating Patient Outcomes: A User’s Guide. Patient Registries
- Zhang, 2019, Mol Genet Genomic Med, 7, e916, 10.1002/mgg3.v7.9 · DOI
- 2017, Juggling Care and Daily Life: The Balancing Act of the Rare Disease Community
Cited by
Items 101–117 of 117
Herce-Hagiwara, B., McKenna, A., Makam, A. N., Richardson, M., Lee, W., Phillips, M., Rind, D. M., & Agboola, F. O. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.8.835 · Cited by 2
Erbliche Netzhauterkrankungen: aktuelle Therapiemöglichkeiten und zukünftige Therapieperspektiven
Pfau, K., & Kellner, U. (2025) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2521-4616
Erbliche Netzhauterkrankungen: aktuelle Therapiemöglichkeiten und zukünftige Therapieperspektiven
Pfau, K., & Kellner, U. (2025) · Augenheilkunde up2date · doi:10.1055/a-2651-3591
Varela, M. D., Aychoua, N., Rashid, M., Lopes, A., & Michaelides, M. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.101026
Self-citationPsychosocial observations in ocular genetics consultations: from genetic diagnosis to rehabilitation
de Vasconcellos, C. F. C., Pellissari, M. C., Salles, M. V., & Sallum, J. M. F. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03880-0
Tang, H.-M., Tang, Y., Ni, S.-H., Du, Y., & Yang, Z.-Q. (2025) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2025.12.006
Stephenson, K. A. J., Zhu, J., Wynne, N., Dockery, A., Cairns, R. M., Duignan, E. S., Whelan, L., Malone, C. P., Dempsey, H., Collins, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14545275
Self-citationStephenson, K. A. J., Zhu, J., Wynne, N., Dockery, A., Cairns, R. M., Duignan, E. S., Whelan, L., Malone, C. P., Dempsey, H., Collins, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14545272
Self-citationAdditional file 1 of Cost-of-illness studies of inherited retinal diseases: a systematic review
Ng, Q. X., Ong, C., Yaow, C. Y. L., Chan, H. W., Thumboo, J., Wang, Y., & Koh, G. C. H. (2024) · Figshare · doi:10.6084/m9.figshare.26687112
The Genetics of Color Vision and Congenital Color Deficiencies
Hunt, D. M., & Carvalho, L. S. (2026) · Springer series in vision research · doi:10.1007/978-3-032-09457-5_1
Durno, N. S., Denee, T. R., Pantiri, K., Chattopadhyay, D., Pungor, K., Oinasmaa, S. P., Siddiqui, K., & Arkell, K. R. (2026) · Advances in Therapy · doi:10.1007/s12325-025-03485-0
Grewal, B. K., Britten‐Jones, A. C., Metha, A. B., Bedggood, P. A., & Ayton, L. N. (2026) · Expert Review of Ophthalmology · doi:10.1080/17469899.2026.2645147
Denee, T. R., Lahaye, M., Pungor, K., Denderen, J. V., Brémond‐Gignac, D., Lotery, A. J., Parmeggiani, F., Paudel, N., Rodríguez-de-la-Rúa-Franch, E., Rotenstreich, Y., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2654325
SCHOFIELD, D. J., Kraindler, J., Shrestha, R. N., Tan, O., West, S., Hart, N., Wall, L., Tan, L., Hewett, D., Villaret, L., et al. (2026) · Eye · doi:10.1038/s41433-026-04532-y
Global disparities in inherited retinal disease: A scoping review
Yu, J. H., Adams, A. R., See, W. Y. N., & Ahmed, I. (2026) · AJO International · doi:10.1016/j.ajoint.2026.100299
A national cross-sectional study of patients with inherited retinal disease in China
Zhang, Y., Chen, M., Duan, Z., Yang, P., Xie, L., & Zhisheng, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-70895-7
Verma, S. S., Wang, Y., Hu, W., Zhu, Z., Rahi, J., Ge, Z., He, M., Zhou, Y., Keane, P. A., & Wagner, S. K. (2026) · Ophthalmic Epidemiology · doi:10.1080/09286586.2026.2739999
Metadata
- Authors
- Galvin, O., Chi, G., Brady, L., Hippert, C., Del Valle Rubido, M., Daly, A., & Michaelides, M.
- Affiliations
- Roche (United States) (US)
- Fighting Blindness (IE)
- F. Hoffmann-La Roche AG (CH)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Corresponding author
- Galvin, Orla
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2020-03
- Volume
- Volume 14
- Pages
- 707-719
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC7062501
- OpenAlex
- W3009621895
- Cited by
- 116
- References
- 32
- Citations by year
- 2026: 9 · 2025: 27 · 2024: 20 · 2023: 17 · 2022: 24 · 2021: 16 · 2020: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Retina UK
- ProQR Therapeutics
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- inherited retinal disease, economic burden, disability-adjusted life years, prevalence, access to genetic testing, genetic counseling, employment discrimination, informal care, health system costs, deadweight loss, value for money, patient and family impact, Ireland, United Kingdom, health policy planning, clinical trial access, patient registry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
